Valiltramiprosate

A drug candidate for Alzheimer's disease

Valiltramiprosate
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	157604-28-1
PubChem	6918636
DrugBank
ChemSpider	5293734
KEGG	D08895

Valiltramiprosate is a drug candidate that was investigated for the treatment of Alzheimer's disease. It is a derivative of tramiprosate, which is a compound that was initially studied for its potential to inhibit the aggregation of amyloid-beta peptides, a hallmark of Alzheimer's pathology.

Chemical Structure and Properties

Chemical structure of Valiltramiprosate

Valiltramiprosate is chemically known as (2S)-2-amino-3-(3-methylbutanoylamino)propanoic acid. It is a small molecule with the molecular formula C₉H₁₈N₂O₃. The compound is characterized by the presence of an amino acid backbone with a valine moiety, which is thought to enhance its ability to interact with amyloid-beta peptides.

Mechanism of Action

Valiltramiprosate is designed to interfere with the aggregation of amyloid-beta peptides into plaques, which are believed to play a critical role in the pathogenesis of Alzheimer's disease. By preventing or reducing the formation of these plaques, Valiltramiprosate aims to slow down the progression of the disease and alleviate cognitive symptoms.

Clinical Development

Valiltramiprosate was developed following the initial studies on tramiprosate, which showed some promise in preclinical models. However, clinical trials of tramiprosate did not demonstrate significant efficacy in patients with Alzheimer's disease. Valiltramiprosate was subsequently developed as a modified version with potentially improved pharmacokinetic properties.

Challenges and Future Directions

The development of Valiltramiprosate, like many other Alzheimer's treatments, faces significant challenges. The complexity of Alzheimer's disease, with its multifactorial etiology, makes it difficult to target a single pathway effectively. Future research may focus on combination therapies that target multiple aspects of the disease simultaneously.

Related Pages

• Alzheimer's disease
• Amyloid-beta
• Tramiprosate
• Neurodegenerative disease